BCBA/RICH (BCBA/RICH)

Buenos Aires Stock Exchange: BCBA/RICH · ARS

ARS 1,290

-89.97 (-6.5%)· Recorded snapshot

Market cap	104.2B
Revenue (ttm)	114B
Net income (ttm)	12.5B
EPS (ttm)	ARS 155
Shares out	80.8M
P/E (trailing)	8.3x
Dividend	ARS 26.9 (2.08%)
Volume	939
Beta	-0.63

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 114B
Net income (ttm): 12.5B
EPS (ttm): ARS 155
P/E (trailing): 8.3x
Market cap: 104.2B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E8.3

P25 n/aP50 n/aP75 n/a

ROE13.2

P25 n/aP50 n/aP75 n/a

ROIC3.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All BCBA/RICH indicators

Market & fundamental data

Available fields

228

Groups with data

Currency

ARS

Showing 228 of 228 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	ARS
Country	Argentina
Country code	AR
Earnings date	2026-11-06
Employees	620
Employees change	0
Employees growth	0%
Enterprise value	ARS 345B
Exchange	Buenos Aires Stock Exchange
Financial currency	ARS
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	December
Founded	1959
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	Yes
ISIN number	ARLRIC300027
Last earnings date	2025-11-07
Last refreshed	2026-10-29
Market cap	ARS 104.2B
Next earnings date	2026-11-06
Price	ARS 1,290.00
Price currency	ARS
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-29
Symbol	bcba/RICH
Website	https://www.richmondlab.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (3Y)	14.98x
Average P/E ratio (5Y)	26.65x
Earnings yield	12%
EV/Earnings	28.17x
EV/EBIT	19.8x
EV/EBITDA	18.63x
EV/FCF	48.64x
EV/Sales	3.09x
FCF / EV yield	2.06%
FCF yield	6.5%
Graham number	2254.93315
Graham upside	63.4%
Lynch fair value	ARS 3,871.31
Lynch upside	180.53%
P/B ratio	0.94x
P/E ratio	8.33x
P/FCF ratio	15.39x
P/OCF ratio	10.5x
P/S ratio	0.98x
Price / tangible book value	1.01x
Price/EBITDA ratio	6.1x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	15.66%
EBITDA margin	16.03%
Effective tax rate	29.52%
FCF margin	6.35%
Gross margin	61.99%
Operating margin	15.66%
Pretax margin	16.08%
Profit margin	10.97%
Profit per employee	ARS 20.2M
Profitable years	2
Revenue per employee	ARS 183.9M
ROA	2.9%
ROA (5Y)	5.42%
ROCE	5.26%
ROE	13.21%
ROE (5Y)	1.52%
ROIC	3.53%
ROIC (5Y)	6.79%
Tax / revenue	4.75%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-35.78%
EPS growth 10Y	77.29%
EPS growth 5Y	81.51%
EPS growth years	0
FCF growth (QoQ)	214.69%
Gross profit growth	-17.7%
Gross profit growth (Q)	-16.55%
Gross profit growth 3Y	22.51%
Gross profit growth 5Y	62.56%
Net income growth	-35.79%
Net income growth 5Y	81.49%
Net income growth years	0
OCF growth	-18.89%
OCF growth (QoQ)	162.59%
Operating income growth	-32.95%
Operating income growth (Q)	-86.22%
Operating income growth 3Y	24.86%
Operating income growth 5Y	41.61%
Revenue growth	-22.29%
Revenue growth (Q)	-13.57%
Revenue growth (QoQ)	6.87%
Revenue growth 10Y	69.92%
Revenue growth 3Y	14.02%
Revenue growth 5Y	55.23%
Revenue growth quarters	11
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	ARS -3.4B
Depreciation and amortization	ARS 422.7M
EBIT	ARS 17.9B
EBITDA	ARS 18.3B
EPS	ARS 154.85
FCF per share	ARS 89.67
Financing cash flow	ARS 5.5B
Free cash flow	ARS 7.2B
Gross profit	ARS 70.7B
Income taxes	ARS 5.4B
Investing cash flow	ARS -14.6B
Net borrowing	ARS 5.4B
Net cash flow	ARS -1.6B
Net income	ARS 12.5B
Operating income	ARS 17.9B
Revenue	ARS 114B

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	0.72
Book value per share	ARS 1,459.37
Debt / EBITDA	12.83
Debt / equity	2.05
Debt / FCF	33.63
Goodwill	ARS 6.7B
Interest coverage	0.98
Long-term assets	ARS 347.6B
Long-term liabilities	ARS 220.4B
Net cash (debt)	ARS -239.6B
Net cash / market cap	-215.04%
Net debt / EBITDA	13.11
Net debt / equity	2.01
Net debt / FCF	33.09
Piotroski F-Score	4
Property, plant and equipment	ARS 285.2B
Shareholders' equity	ARS 119B
Tangible book value	ARS 110.6B
Tangible book value per share	ARS 1,369.40
Total assets	ARS 446.9B
Total cash	ARS 3.9B
Total debt	ARS 243.5B
Total liabilities	ARS 327.9B
WACC	3.86%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.3
Current assets	ARS 99.3B
Current liabilities	ARS 107.6B
Current ratio	0.92
Inventory turnover	1.08
Net working capital	ARS 36.2B
Quick ratio	0.49
Working capital	ARS -8.2B
Working capital turnover	-29.13

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.01%
Dividend growth	21.29%
Dividend growth (3Y)	172.3%
Dividend growth (5Y)	125.87%
Dividend growth years	3
Dividend payment date	2026-06-16
Dividend payment years	2
Dividend payout frequency	Semi-Annual
Dividend per share	ARS 26.89
Dividend yield	2.08%
Ex-dividend date	2026-06-12
FCF payout ratio	36.37%
Last dividend	ARS 16.51
Payout ratio	21.06%
Shareholder yield	1.96%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	ARS 1,564.30
1D price change	-6.52%
1M price change	-9.72%
1M total return	-9.72%
1W price change	-6.14%
1W total return	-6.14%
1Y price change	-9.41%
1Y return CAGR	-7.53%
1Y total return	-7.53%
20-day SMA	ARS 1,421.00
200-day SMA	ARS 1,633.43
3M price change	-15.58%
3M total return	-15.58%
3Y price change	87.73%
3Y return CAGR	25%
3Y total return	95.34%
50-day SMA	ARS 1,494.90
50-day SMA vs 200-day SMA	50under200
52-week high	ARS 2,300.00
52-week high date	2025-12-11
52-week low	ARS 1,290.00
52-week low date	2026-10-27
5Y price change	451.43%
5Y return CAGR	42.02%
5Y total return	477.67%
6M price change	-20.97%
6M total return	-19.33%
All-time high	ARS 2,300.00
All-time high date	2025-12-11
All-time low	ARS 24.80
All-time low date	2018-07-02
Average true range (ATR)	ARS 70.81
Average volume	3K
Beta (1Y)	0.13
Beta (2Y)	0.11
Beta (5Y)	-0.63
Change from 52-week high	-43.91%
Change from 52-week low	0%
Change from all-time high	-43.48%
Change from all-time low	5,141.94%
Change from open	-6.52%
Day's gap	0%
Dollar volume	ARS 1.2M
High price	ARS 1,380.00
Low price	ARS 1,290.00
Monthly RSI	45.63
Open price	ARS 1,380.00
Position in 52-week range	0%
Previous close	ARS 1,380.00
Price vs 150-day SMA	-16.9%
Price vs 20-day SMA	-8.52%
Price vs 200-day SMA	-20.41%
Price vs 50-day SMA	-13.04%
Relative volume	0.31
RSI	38.24
Sharpe ratio	0.5
Sharpe ratio (3Y)	0.8
Sharpe ratio (5Y)	0.94
Sortino ratio	0.96
Sortino ratio (3Y)	1.45
Sortino ratio (5Y)	1.7
Volume	939
Weekly RSI	24.97
YTD price change	-34.18%
YTD total return	-32.81%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	14.2M
Shares change (QoQ)	0%
Shares change (YoY)	-0.01%
Shares held by insiders	38.54%
Shares outstanding	80.8M

Deeper analysis on BCBA/RICH

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BCBA/RICH report

Is a complete BCBA/RICH research report available?

No complete published report is available for bcba/RICH (BCBA/RICH) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

BCBA/RICH (BCBA/RICH)

Price

Financial snapshot

Fair-value bridge

Latest news · BCBA/RICH

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BCBA/RICH indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BCBA/RICH

Frequently asked questions